Immuno-Oncology biomarkers 2010 and beyond

Perspectives from the iSBTc/SITC biomarker task force

Lisa H. Butterfield, Mary L. Disis, Samir N. Khleif, James M. Balwit, Francesco M. Marincola

Research output: Contribution to journalComment/debate

22 Citations (Scopus)

Abstract

The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.

Original languageEnglish (US)
Article number130
JournalJournal of Translational Medicine
Volume8
DOIs
StatePublished - Dec 7 2010

Fingerprint

Oncology
Biomarkers
Advisory Committees
Immunotherapy
Immunologic Monitoring
Assays
National Institutes of Health (U.S.)
Tumor Biomarkers
Immunity
Industry
Research Personnel
Standardization
Technology
Websites
Health
Monitoring
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immuno-Oncology biomarkers 2010 and beyond : Perspectives from the iSBTc/SITC biomarker task force. / Butterfield, Lisa H.; Disis, Mary L.; Khleif, Samir N.; Balwit, James M.; Marincola, Francesco M.

In: Journal of Translational Medicine, Vol. 8, 130, 07.12.2010.

Research output: Contribution to journalComment/debate

Butterfield, Lisa H. ; Disis, Mary L. ; Khleif, Samir N. ; Balwit, James M. ; Marincola, Francesco M. / Immuno-Oncology biomarkers 2010 and beyond : Perspectives from the iSBTc/SITC biomarker task force. In: Journal of Translational Medicine. 2010 ; Vol. 8.
@article{0e5e0d949fe54bd28e1625e81f3acb2f,
title = "Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force",
abstract = "The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.",
author = "Butterfield, {Lisa H.} and Disis, {Mary L.} and Khleif, {Samir N.} and Balwit, {James M.} and Marincola, {Francesco M.}",
year = "2010",
month = "12",
day = "7",
doi = "10.1186/1479-5876-8-130",
language = "English (US)",
volume = "8",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Immuno-Oncology biomarkers 2010 and beyond

T2 - Perspectives from the iSBTc/SITC biomarker task force

AU - Butterfield, Lisa H.

AU - Disis, Mary L.

AU - Khleif, Samir N.

AU - Balwit, James M.

AU - Marincola, Francesco M.

PY - 2010/12/7

Y1 - 2010/12/7

N2 - The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.

AB - The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.

UR - http://www.scopus.com/inward/record.url?scp=78649750575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649750575&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-8-130

DO - 10.1186/1479-5876-8-130

M3 - Comment/debate

VL - 8

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 130

ER -